Gemfibrozil-xenopus glucagon-like peptide-1 derivative and application thereof

A technology of glucagon and Xenopus laevis, which is applied in the direction of glucagon, hormone peptides, specific peptides, etc., can solve the problem of loss of biological activity, etc., to prolong the time of hypoglycemic action, prolong the biological half-life, and improve stability Effect
CN110759991AActive Publication Date: 2020-02-07南京赛诺生物制药有限公司
6 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
南京赛诺生物制药有限公司
Publication Date
2020-02-07

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a gemfibrozil-xenopus glucagon-like peptide-1 derivative. The gemfibrozil modified XenGLP-1 (xenopus glucagon-like peptide-1) derivative is prepared by structurally modifyinga side chain of XenGLP-1, and introducing a micromolecular gemfibrozil derivative with a high serum protein binding rate and a high lipid-lowering effect. The invention provides an application of thederivative in preparation of a medicine and a composition containing the derivative. The XenGLP-1 derivative has high lipid-lowering activity which other GLP-1 medicines do not have, and at the same time, also has high stability, high blood sugar reduction activity and long blood sugar reduction action time.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a class of Xenopus glucagon-like peptide-1 (XenGLP-1) derivatives and applications thereof Background technique

[0002] Diabetes mellitus is a metabolic disease characterized by hyperglycemia and one of the most important chronic non-communicable diseases in the world. Diabetes can be divided into insulin-dependent diabetes (type 1) and non-insulin-dependent diabetes (type 2), of which type 2 diabetes accounts for more than 85% of the number of diabetic patients. According to the latest survey data from the International Diabetes Federation (IDF), the total number of diabetic patients in the world in 2019 was 463 million. It is estimated that by 2045, the number of people with diabetes will reach 700 million. Among them, China is the country with the largest number of patients. In 2019, the number of diabetic patients in China has reached 143 million, which has seriously affected health and social economy. Currently the mos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More